Obesity
Obesity
Addressing Obesity
For over 15 years, Schaeffer researchers have examined obesity’s consequences for government budgets, including Medicare and Social Security, the impact it has on individuals’ health outcomes, and the value of new interventions and treatments.
Related Topics
Top Stories View All
News
White House Move to Expand Obesity Drug Access Informed by Schaeffer Research
In The News View All
NPR
Joyce interviewed about White House deal lowering prices on anti-obesity medications
Featured Experts: Geoffrey Joyce
CNBC
Lakdawalla discusses how White House obesity deal will broaden access
Featured Experts: Darius Lakdawalla
The Academic Minute
Chapel discusses his “diabetes paradox” research showing health gains haven’t led to labor gains among people with diabetes
Featured Experts: Jack M. Chapel
Reuters
As insurers cut back on GLP-1 coverage, Peters says some patients are stretching doses
Featured Experts: Anne Peters
STAT
Expanded coverage of GLP-1s is “probably the single most effective policy” for improving public health, Goldman says
Featured Experts: Dana Goldman
Featured White Paper
Benefits of Medicare Coverage for Weight Loss Drugs
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Experts: Alison Sexton Ward, Bryan Tysinger, PhuongGiang Nguyen, Dana Goldman, Darius Lakdawalla
Scholar Testimony
Testimony on Incentivizing Chronic Disease Prevention and Treatment
Rebalancing the healthcare system to favor prevention and cures can potentially reduce the long-term burden of obesity and other chronic diseases, Senior Scholar Anne Peters testified before the House Ways and Means health subcommittee.
Read the Testimony
